Answers are grounded in this paper and cite their sources.
// Juan Tornin 1 , Lucia Martinez-Cruzado 1 , Laura Santos 1 , Aida Rodriguez 1 , Luz-Elena Núñez 2 , Patricia Oro 2 , Maria Ana Hermosilla 2 , Eva Allonca 1 , Maria Teresa Fernández-García 3 , Aurora Astudillo 4 , Carlos Suarez 1 , Francisco Morís 2 , Rene Rodriguez 1 1 Hospital Universitario Central de Asturias and Instituto Universitario de Oncología del Principado de Asturias, Oviedo, Spain 2 EntreChem SL, Oviedo, Spain 3 Unidad Histopatología Molecular en Modelos Animales de Cáncer, IUOPA, Universidad de Oviedo, Oviedo, Spain 4 Servicio de Anatomía Patológica, Hospital Universitario Central de Asturias, Oviedo, Spain Correspondence to: Rene Rodriguez, e-mail: renerg@ficyt.es Keywords: myxoid liposarcoma, mesenchymal stem cells, cancer stem cells, mithralog EC-8042, DIG-MSK Received: November 03, 2015 Accepted: March 28, 2016 Published: April 18, 2016 ABSTRACT Tumor initiating cells (TICs), responsible for tumor initiation, and cancer stem cells (CSCs), responsible for tumor expansion and propagation, are often resistant to chemotherapeutic agents. To find therapeutic targets against sarcoma initiating and propagating cells we used models of myxoid liposarcoma (MLS) and undifferentiated pleomorphic sarcoma (UPS) developed from human mesenchymal stromal/stem cells (hMSCs), which constitute the most likely cell-of-origin for sarcoma. We found that SP1-mediated transcription was among the most significantly altered signaling. To inhibit SP1 activity, we used EC-8042, a mithramycin (MTM) analog (mithralog) with enhanced anti-tumor activity and highly improved safety. EC-8042 inhibited the growth of TIC cultures, induced cell cycle arrest and apoptosis and upregulated the adipogenic factor CEBPα. SP1 knockdown was able to mimic the anti-proliferative effects induced by EC-8042. Importantly, EC-8042 was not recognized as a substrate by several ABC efflux pumps involved in drug resistance, and, opposite to the chemotherapeutic drug doxorubicin, repressed the expression of many genes responsible for the TIC/CSC phenotype, including SOX2 , C-MYC , NOTCH1 and NFκB1 . Accordingly, EC-8042, but not doxorubicin, efficiently reduced the survival of CSC-enriched tumorsphere sarcoma cultures. In vivo , EC-8042 induced a profound inhibition of tumor growth associated to a strong reduction of the mitotic index and the induction of adipogenic differentiation and senescence. Finally, EC-8042 reduced the ability of tumor cells to reinitiate tumor growth. These data suggest that EC-8042 could constitute an effective treatment against both TIC and CSC subpopulations in sarcoma.
No takes yet. Share an insight, caveat, or question.
Tornín et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: